Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.465 USD | +3.12% | +17.69% | +49.14% |
Mar. 20 | North American Morning Briefing : Markets on Hold -2- | DJ |
Mar. 19 | JPMorgan Upgrades Mersana Therapeutics to Neutral From Underweight, Price Target is $5 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+49.14% | 411M | |
-1.15% | 103B | |
+8.69% | 101B | |
+4.40% | 23.07B | |
-12.28% | 22.23B | |
-4.36% | 18.05B | |
-39.98% | 17.18B | |
-10.45% | 16.94B | |
+7.17% | 14.07B | |
+38.63% | 12.35B |
- Stock Market
- Equities
- MRSN Stock
- News Mersana Therapeutics, Inc.
- Wedbush Upgrades Mersana Therapeutics to Outperform From Neutral, Notes Increased Confidence in Program; Adjusts PT to $7 From $2